Manufacturing, Cell Therapies

June 10th 2025

The industry is diversifying pipelines from traditional small-molecule drugs to embrace complex and exciting new modalities.

May 28th 2025

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.

May 14th 2025

The company’s technology was used to create CAR-T cells that demonstrated the expression of complex CARs in a single DNA donor.

March 28th 2025

Having completed its €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in R&D that has driven the growth of Slovenia’s workforce.